CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that clinical findings for three different TAP compounds for the treatment of solid tumors are to be reported at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to take place June 1-5, 2007 in Chicago, IL.
